England’s NHS adopts rapid immunotherapy jab, but systemic cancer drivers remain unaddressed amid profit-driven oncology
Original framing: “Thousands of cancer patients in England to benefit from new immunotherapy jab” — The Guardian - World
Future scenarios suggest that immunotherapy alone cannot curb rising cancer rates without addressing environmental carcinogens and social inequities; by 2040, global cancer cases are projected to rise by 50% without systemic changes. Alternative models, such as the WHO’s *Health in All Policies* framework, propose integrating cancer prevention into urban planning, food systems, and labour regulations. The current trajectory risks deepening disparities, as high-cost treatments become accessible only to wealthy nations or private patients.
The NHS’s adoption of pembrolizumab reflects a broader biomedical paradigm that treats cancer as a molecular puzzle solvable through high-tech interventions, while systemic drivers—industrial carcinogens, corporate impunity, and structural inequities—remain unchallenged.
This approach mirrors historical patterns where medical innovations (e.g., chemotherapy, statins) were celebrated as panaceas, only to reveal their limitations when confronted with root causes like environmental degradation and social determinants. Indigenous and cross-cultural perspectives offer a corrective, framing cancer as a communal and ecological disruption requiring holistic healing, but these voices are marginalised in favour of pharmaceutical solutions. The trickster’s irony lies in the NHS’s haste to deploy a £1bn treatment while neglecting the £10bn in annual costs from preventable cancers—a contradiction that exposes the absurdity of a system prioritising profit over people and planet. True progress demands a paradigm shift: integrating immunotherapy into a preventive, decolonised, and equitable health framework, where the cure is not just a jab but a transformation of the conditions that breed disease.